The Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy designation (BTD) for the combination of fruquintinib and sintilimab (a PD-1 antibody), which is being developed by Hong Kong-based Hutchmed (HKEX:13; AIM: HCM)), whose London listed shares dipped 2.6% to 192.48 pence this morning.
The combo therapy is intended for the treatment of patients with advanced endometrial cancer (EMC) with pMMR tumors that have failed at least one line of platinum-based therapy.
A study for potential registration of this combination in patients with previously treated advanced EMC in China has recently completed enrollment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze